OPRX vs. RMNI, ZFOX, DHX, STCN, EGIO, MCHX, EEX, RGP, ZH, and LQDT Should you be buying OptimizeRx stock or one of its competitors? The main competitors of OptimizeRx include Rimini Street (RMNI), ZeroFox (ZFOX), DHI Group (DHX), Steel Connect (STCN), Edgio (EGIO), Marchex (MCHX), Emerald (EEX), Resources Connection (RGP), Zhihu (ZH), and Liquidity Services (LQDT). These companies are all part of the "business services, not elsewhere classified" industry.
Rimini Street (NASDAQ:RMNI ) and OptimizeRx (NASDAQ:OPRX ) are both small-cap computer and technology companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
Rimini Street has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Rimini Street, indicating that it is currently the more affordable of the two stocks.
Rimini Street received 9 more outperform votes than OptimizeRx when rated by MarketBeat users. Likewise, 63.49% of users gave Rimini Street an outperform vote while only 63.16% of users gave OptimizeRx an outperform vote.
73.8% of Rimini Street shares are held by institutional investors. Comparatively, 76.5% of OptimizeRx shares are held by institutional investors. 41.3% of Rimini Street shares are held by company insiders. Comparatively, 4.4% of OptimizeRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Rimini Street has a net margin of 5.02% compared to Rimini Street's net margin of -23.10%. Rimini Street's return on equity of -6.96% beat OptimizeRx's return on equity.
In the previous week, OptimizeRx had 13 more articles in the media than Rimini Street. MarketBeat recorded 15 mentions for OptimizeRx and 2 mentions for Rimini Street. OptimizeRx's average media sentiment score of 0.89 beat Rimini Street's score of 0.11 indicating that Rimini Street is being referred to more favorably in the media.
Rimini Street presently has a consensus target price of $4.50, suggesting a potential upside of 85.95%. OptimizeRx has a consensus target price of $16.00, suggesting a potential upside of 26.08%. Given OptimizeRx's higher possible upside, research analysts clearly believe Rimini Street is more favorable than OptimizeRx.
Rimini Street has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, OptimizeRx has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Summary Rimini Street beats OptimizeRx on 12 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding OPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
OptimizeRx Competitors List
Related Companies and Tools
